ANDA 79049, held by Chartwell Rx. Alendronate Sodium.
As of Nov 16, 2026, ANDA 79049 (Alendronate Sodium), held by Chartwell Rx, was first approved by FDA on Aug 4, 2008, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 4, 2008 | Original application | Approved | None posted |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 5MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Nov 19, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 19, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 29, 2011 | Supplement 3REMS | Approved | None posted |
| May 17, 2011 | Supplement 2Labeling | Approved | None posted |
| Aug 4, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters